| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | Mgn; HESL; HCM1228; bHLHb44 |
| WB Predicted band size | 27 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human HELT |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下为3篇关于HELT抗体的示例文献(注：HELT抗体相关研究较为小众，以下内容为模拟虚构，供参考)：
---
1. **文献名称**：*HELT Antibody Characterization in Autoimmune Disease Models*
**作者**：Smith J, et al.
**摘要**：本研究首次报道了HELT抗体在系统性红斑狼疮(SLE)患者血清中的异常表达，并通过免疫印迹和流式细胞术验证其与T细胞亚群表面抗原的结合能力，提示HELT可能参与自身免疫反应的调控。
2. **文献名称**：*Structural Analysis of HELT Epitope Recognition by Monoclonal Antibodies*
**作者**：Chen L, Wang H.
**摘要**：通过X射线晶体学解析HELT抗原-抗体复合物结构，揭示了HELT抗体的高亲和力结合位点位于靶蛋白的α螺旋结构域，为开发基于HELT抗体的靶向疗法提供理论依据。
3. **文献名称**：*HELT as a Novel Biomarker in Solid Tumors: Diagnostic Potential of Anti-HELT Antibodies*
**作者**：Gomez R, et al.
**摘要**：研究发现HELT抗原在肺癌和乳腺癌组织中高表达，利用抗HELT抗体的免疫组化检测显示其在癌症早期诊断中具有高敏感性和特异性，可能成为新型肿瘤标志物。
---
**备注**：目前公开数据库中关于“HELT抗体”的文献较少，建议确认术语准确性(如是否为“Helios抗体”或“HEL-T抗体”)，或补充更多研究背景以优化检索。如需真实文献，可通过PubMed/Google Scholar以关键词组合(如“HELT antibody”“HELT antigen”)进一步筛查。
The HELT antibody targets the transcription factor HELT (HES/HEY-like transcription factor), a member of the HES-related repressor protein family. HELT contains a basic helix-loop-helix (bHLH) domain and functions as a transcriptional repressor, primarily regulating neurogenesis and lymphoid development. It interacts with Notch signaling pathways, playing a role in neural progenitor maintenance and T-cell differentiation by suppressing differentiation-promoting genes. HELT is expressed in embryonic tissues, the central nervous system, and immune cells.
HELT antibodies are essential tools for studying its expression patterns, subcellular localization, and interactions in developmental and disease contexts. Researchers employ these antibodies in techniques like immunohistochemistry, Western blotting, and flow cytometry to explore HELT's involvement in neurodevelopmental disorders, hematopoiesis, and cancer. Dysregulation of HELT has been implicated in T-cell malignancies and gliomas, highlighting its potential as a therapeutic target.
Current studies focus on elucidating HELT's precise mechanisms in cell fate determination and its crosstalk with signaling pathways like Notch and Wnt. The antibody's specificity and reliability are critical for validating experimental models and clinical correlations, advancing understanding of HELT's dual roles in development and disease.
×
